Roche’s top-selling trio of cancer blockbusters face biosim attack in the U.S. this year, but the Swiss drugmaker just scored an FDA nod for a brand-new oncology drug that might help it pick up the sales slack. More: Roche snags
read moreDuchenne muscular dystrophy drug Emflaza drew fire after it was first approved for its $85,000 price tag. Now, the drug has a new owner, a new list price—$35,000 after discounts—and an expanded label, thanks to an FDA approval in younger
read moreA small company that is all about development of dermatology drugs has snagged a new investor and will soon start on a manufacturing facility that will catapult it into the CDMO market. More: Tergus Pharma to become full-fledged CDMO with
read moreSanofi’s Toujeo has been battling it out against Novo Nordisk’s Tresiba in the next-generation basal insulin market, but new data could give it an edge in one key pool of diabetes patients. More: ADA: Sanofi's Toujeo tops Novo Nordisk's Tresiba
read moreAfter Mylan posted first-quarter earnings, investors punished the company by sending shares down 24%. But as one analyst observed at the time, the decline was about more than just profits and losses. And now, the company is facing new backlash.
read moreThe biomarker is the first and only in vitro diagnostic ROS1 immunohistochemistry assay on the market. More: Roche launches first in vitro lung cancer diagnostic test Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals